Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 1)
Women's Health | Pregnancy, Childbirth and the Puerperium
What is the purpose of this trial?
The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
- Ages18 years and older
- GenderFemale only
- Trial withObsEva SA
- Start Date08/29/2018
- End Date07/31/2019
- Last Updated07/15/2021
- Study HIC#2000021141